Stocktoria

Upstream Bio, Inc. UPB

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2024-10-11

Upstream Bio, Inc. statistics & valuation

Market cap$322.2M
P / B0.9×
Net margin-5026.0%
Return on equity-42.2%
FCF margin-4675.5%
Return on capital-47.1%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Net margin (%)
-862.90% -2650.00% -5026.00% 202320242025
Gross margin (%)
202320242025
Operating margin (%)
-1685.50% -3281.20% -5618.80% 202320242025
Return on equity (%)
-13.40% -42.20% 202320242025
Shares outstanding
3.0M 53.6M 54.2M 202320242025
Net debt ($)
202320242025
Share buybacks ($)
202320242025
Return on assets (%)
-17.50% -13.00% -40.50% 202320242025
Free cash flow margin (%)
-1599.60% -2518.30% -4675.50% 202320242025
Debt / equity (×)
202320242025
EPS ($)
-$12.95 -$5.58 -$2.66 202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023
Operating margin-5618.8%-3281.2%-1685.5%
Net margin-5026.0%-2650.0%-862.9%
FCF margin-4675.5%-2518.3%-1599.6%
Return on assets-40.5%-13.0%-17.5%
Return on equity-42.2%-13.4%16.7%
Current ratio26.1544.6317.96

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.